INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 265 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2022. The put-call ratio across all filers is 0.88 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,362,726 | -41.7% | 26,161 | -29.1% | 0.01% | -41.7% |
| Q2 2023 | $2,336,191 | +20.7% | 36,895 | +3.2% | 0.01% | +20.0% |
| Q1 2023 | $1,936,187 | +107.9% | 35,756 | +103.2% | 0.01% | +100.0% |
| Q4 2022 | $931,233 | +81.5% | 17,597 | +59.6% | 0.01% | +66.7% |
| Q3 2022 | $513,000 | -12.3% | 11,025 | +7.5% | 0.00% | -25.0% |
| Q2 2022 | $585,000 | +195.5% | 10,253 | -61.4% | 0.00% | +300.0% |
| Q3 2019 | $198,000 | +20.0% | 26,556 | +132.4% | 0.00% | 0.0% |
| Q4 2017 | $165,000 | – | 11,425 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
| Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
| DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
| Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
| Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
| Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
| TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |